30 closest matches · ranked by relevance
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
Breast Neoplasms
Primary: Clinical Benefit Rate (CR Plus PR Plus SD) — 0; 0; 3; 1 participants
Breast Cancer
Primary: Change in Primary Tumor FFNP Uptake Before and After Estradiol Challenge as Measured by Percent Change in Standardized Uptake Value (SUV) — 11.0 percent change in SUV
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Breast Cancer
Primary: Median Progression Free Survival (PFS) — 7.2 months
Metastatic Breast Cancer
Primary: Response Rate (RR) — 4.8; 0 percentage of participants
Breast Cancer
Primary: Pathologic Complete Response — 5; 1; 4; 2 Participants
Breast Cancer
Primary: 2-Year Treatment Discontinuation Rate — 31 percentage of participants — p=0.0011
Breast Cancer
Primary: Percentage of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Specimens Using Immunohistochemistry (IHC) and Silver In-Situ…
Breast Cancer Metastatic
Primary: Progression-free Survival (PFS) — 5 months
Estrogen Receptor-positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Cancer
Primary: Number of Participants With Grade 4 Toxicity
Neoplasms
Primary: Progression-free Survival (PFS) - Phase II Part — 7.3; 5.6 Months — p=0.9057
Breast Cancer · Stage II Breast Cancer · Stage III Breast Cancer
Primary: Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings — 23; 0 Participants
HER2-Positive Breast Carcinoma · Hormone Receptor-Positive Breast Carcinoma · Stage IB Breast Cancer AJCC v7
Primary: Percent of Patients With Pathological Complete Response (pCR) in the Breast and Post Therapy Lymph Nodes — 41.2; 45.8 percentage of participants
Metastatic Beast Cancer
Primary: Progression-free Survival (PFS) Rate at 3 Months — 50.1 percent of participants
Breast Cancer
Primary: Change From Baseline in Tumor Cell Proliferation, as Measured by the Proportion of Nuclei Staining Ki67-Positive at Surgery Relative to Baseline in Pre- and…
Ductal Breast Carcinoma in Situ · Lobular Breast Carcinoma in Situ · Stage II Breast Cancer
Primary: The Proportion of Patients With RS 11-25 Who Refused the Assigned Treatment — 0.15 proportion of participants
Breast Cancer · Metastasis
Primary: Number of Participants With Objective Response — 0; 1; 1; 1 participants
Hormone Receptor Positive Malignant Neoplasm of Breast · Human Epidermal Growth Factor 2 Negative Carcinoma of Breast · Estrogen Receptor Positive Breast Cancer
Primary: Progression Free Survival (PFS) Per RECIST 1.1 — 9.13 Months
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Breast Cancer
Primary: Percentage of Participants With Immunohistochemical (IHC) Evaluation Between Site A and Others (Sites B, C, D and E) — 16.7; 12.5; 0.0; 8.3 percentage of participants
Breast Cancer
Primary: Pathological Response for Basal Group 2 — 16; 14; 5; 11 Participants
Estrogen Receptor-negative Breast Cancer · Progesterone Receptor-negative Breast Cancer · Recurrent Breast Cancer
Primary: Clinical Benefit Rate (CR + PR + SD > 6 Months). — 7.1; 6.3 Percent of Participants
Breast Neoplasms · Breast Cancer · Estrogen-receptor Positive Breast Cancer
Primary: Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Estrogen Receptor-positive Breast Cancer · Progesterone Receptor-negative Breast Cancer · Progesterone Receptor-positive Breast Cancer
Primary: Best Overall Response — 5; 2 patients with progressive disease
Breast Cancer
Primary: Disease-free Survival — 64; 71; 70 percentage of participants
Breast Cancer
Primary: Change in Percent Expression of Ki67 Measured by Immunohistochemistry (IHC) — -3.6; -5.1; -4.2 Change in percentage expression of ki 67
Ductal Breast Carcinoma in Situ · Estrogen Receptor-positive Breast Cancer
Primary: Difference Between Ki-67 Labeling Index in Tissue Samples Taken at Baseline and Post-treatment — -3.4; -5.1 percentage of 300 DCIS cells
Breast Cancer Female
Primary: Measure Ki67 Index in Highly Hormone-dependent Breast Cancers vs. Those That Are Not — 7; 6; 40 Participants
Invasive Breast Cancer
Primary: 5 Year Distant Disease Free Survival (DDFS) Assessed as Rate of Patients Without Distant Metastases in Subgroup Luminal A vs. Combined Subgroup (Luminal B, HER2…